This study is NOT currently recruiting participants.
Number
15-C-0200
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Completed Study; data analyses ongoing Gender: Male & Female Min Age: 18 Years Max Age: N/A
Referral Letter Required
No
Population Exclusion(s)
Pregnant Women;Children
Keywords
Targeted; Pharmacodynamic; Personalized Medicine; Genomic
Recruitment Keyword(s)
None
Condition(s)
Neoplasms
Investigational Drug(s)
Afatenib Crizotinib
Investigational Device(s)
Intervention(s)
Drug: Afatinib Drug: Osimertinib Drug: Crizotinib Drug: Trametinib Drug: Sunitinib Drug: Vismodegib Drug: Dasatinib Drug: AZD5363 Drug: Binimetinib Drug: Palbociclib Drug: Nivolumab Drug: JNJ-42756493 (Erdafitinib) Drug: Copanlisib Drug: AZD1775 Drug: LOXO-101 Drug: VS-6063 (Defactinib) Drug: Pertuzumab Drug: MLN0128 Drug: AZD4547 Drug: GSK2636771 Drug: Taselisib Drug: Ado-trastuzumab emtansine Drug: Dabrafenib Drug: BMS-986016 Drug: Trastuzumab
Supporting Site
National Cancer Institute
Targeted agents have been shown to benefit many types of cancer. Researchers want to test if people with cancer with certain genetic changes benefit from treatment with agents targeting those changes.
Objective:
To test any good and bad effects of study drugs or drug combinations. Each drug targets specific genetic changes found in some cancers.
Eligibility:
People ages 18 or older with cancer that has become worse after treatment or has no treatment.
Design:
Participants will be screened with:
-Medical history
-Physical exam
-Blood and urine tests
-Chest x-rays
-MRI or CT scans: They will lay in a machine that takes images of the body.
-ECG, ECHO, or MUGA: A machine records heart function.
-Eye exam
-Skin exam
-Tumor biopsy
The tumor sample will be tested for gene changes. If it shows certain changes, participants will be assigned to a particular treatment. Different treatments will target different changes.
Participants will have several visits over many months.
Participants will take a study drug by mouth 1 to 4 times daily. Or they will get a drug through a vein every 3 weeks.
Participants will keep a medicine diary.
After they stop drug treatment, participants will have follow-up exams:
-Every 3 months for 2 years
-Every 6 months for the third year
Participants may be asked to join another MATCH study treatment if:
-Their cancer gets worse
-They can no longer tolerate the treatment
--Back to Top--
INCLUSION CRITERIA: - Adults with histologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy, or for whom no standard therapy exists -Tumor amenable to image guided or direct vision biopsy and willingness to undergo a tumor biopsy for molecular profiling. EXCLUSION CRITERIA: - For each agent (treatment), patients with tumors for which there is an FDA-approved indication, or with histologies that have been shown not to respond or not to have prolonged PFS, will be ineligible.
- Adults with histologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy, or for whom no standard therapy exists
-Tumor amenable to image guided or direct vision biopsy and willingness to undergo a tumor biopsy for molecular profiling.
EXCLUSION CRITERIA:
- For each agent (treatment), patients with tumors for which there is an FDA-approved indication, or with histologies that have been shown not to respond or not to have prolonged PFS, will be ineligible.
Principal Investigator
Referral Contact
For more information: